Print

Takeda San Francisco Appoints Michael Buckley, Ph.D. Vice President of Process Sciences  
10/12/2009 10:36:06 AM

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Takeda San Francisco, Inc. announced today that Michael Buckley, Ph.D., has joined the company as vice president of process sciences. Dr. Buckley will be responsible for directing all aspects of the materials supply to support research and prepare for production of therapeutic antibody candidates at Takeda's antibody IND engine and center of excellence for biologics.

"Mike brings over 20 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D., president and chief scientific officer, Takeda San Francisco. "Mike's extensive experience covers all key aspects of antibody drug production, purification, formulation and analytical development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of discovering and advancing superior therapeutics to contribute to the health of individuals."

Dr. Buckley previously has held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, leading multi-disciplinary groups in process development, manufacturing and materials management. He also has written multiple IND, BLA and drug master file sections for regulatory submissions. While at Corixa, Dr. Buckley was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 antibody (Bexxar(TM)). He holds a Ph.D. in immunology from the UMDNJ Graduate School of Biomedical Sciences, Newark, NJ.

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports Takeda's therapeutic antibody initiative in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda Pharmaceutical Company Limited

Founded in 1781 and located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

SOURCE Takeda San Francisco, Inc.

CONTACT: Patricia Sinatra, Corporate Communications and Public Relations,
Takeda San Francisco, Inc., +1-650-745-9332

Web site: http://www.takedasf.com/


//-->